MENU
Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 08, 2023

$CLLS, $EDIT, and $CRSP: Biotech Trio Skyrockets with a Remarkable +13.25% Weekly Surge

Robots for this industry :
Day Trader, Popular Stocks: Price Action Trading Strategy (TA&FA) - 30-day Annualized Return +33%
Day Trader: High Volatility Stocks for Active Trading (TA&FA) - 30-day Annualized Return +16%

 

Biotechnology companies have been a hotspot in the stock market recently, showing remarkable performance with a notable 13.25% increase in the past week. This impressive upswing is mirrored by the positive outlook for several key tickers in this sector, including CLLS, EDIT, and CRSP. In this article, we will explore the recent developments in these biotechnology companies and highlight key indicators that suggest their continued growth.

Group of Tickers: CLLS, EDIT, CRSP

Positive Outlook with Volume Indicator Backing

The positive outlook for these biotechnology stocks is supported by the Volume Indicator, a metric that signifies strong investor interest and demand for these stocks. Tickeron, a renowned market analysis tool, is optimistic about this group and predicts a further increase of over 4.00% within the next month, with a 56% likelihood. Notably, the daily ratio of advancing to declining volumes within this group was 2.35 to 1, highlighting a strong buying sentiment among investors.

MA50MA10 Indicator Confirms Positive Trend

An important technical indicator, the MA50MA10, has confirmed the positive outlook for one of the tickers in this group. This indicator, with an average accuracy of 90%, suggests a favorable trend for this stock. It's a sign that these biotechnology companies have strong underlying market dynamics supporting their growth.

Market Capitalization Insights

The average market capitalization across this group of biotechnology stocks is approximately 1.6 billion USD. The market cap for individual tickers within the group varies, with CRSP holding the highest valuation at 4 billion USD, while CLLS is the lowest-valued company at 159.1 million USD. These varying market caps reflect the diversity within the biotechnology sector.

High and Low Price Movements

Recent price movements for these stocks have been quite dynamic. On average, these stocks exhibited a weekly price growth of 78.2%, a monthly growth of 41.87%, and a quarterly growth of 0.83%. Notably, CLLS saw the highest weekly price growth at 170.88%, while EDIT experienced the most significant decline at 31.28%.

Key Stock Movements

CRSP's Volatile Week: CRISPR Therapeutics AG (CRSP) experienced a rollercoaster week. On 11/3/23, the stock witnessed a substantial gain of 18.08%, positioning it as a top weekly gainer. However, on 8/3/23, just a day later, CRSP declined by -7.45%, marking it as a top loser for the week. These rapid fluctuations suggest the need for vigilant monitoring of CRSP.

CLLS's Sharp Downturn: Cellectis SA (CLLS) encountered a tough week on 8/3/23, as it emerged as a top weekly loser among penny stocks with a significant drop of -16.52%. Investors should closely analyze the reasons behind this decline and consider the long-term prospects for CLLS.

Volume Surge: Volume has played a crucial role in the recent movements of these stocks. The average weekly volume growth for the group was an astounding 1270.43%, and the monthly and quarterly volume growth were 1064.05% and 1045.67%, respectively. This surge in volume indicates heightened market activity and interest in biotechnology stocks.

Key Technical Indicators for Individual Stocks

  1. CLLS's Aroon Indicator: CLLS's Aroon Indicator entered a downward trend on October 31, 2023. This indicator suggests a potential strong downward move for the stock, with historical data indicating an 85% probability of a downward trend. Current price: $2.52. Support and resistance levels: $2.07 and $3.06, respectively. Recent trends show substantial uptrend growth during October and the week of 10/30/23 - 11/06/23.

  2. EDIT's MACD Histogram: The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 25, 2023, indicating a 79% probability of continued upward momentum. Current price: $8.52. Support and resistance levels: $8.21 and $11.68, respectively. Recent trends show uptrend growth during October and the week of 10/30/23 - 11/06/23.

  3. CRSP's RSI Oscillator: The RSI Oscillator for CRSP moved out of oversold territory on October 23, 2023, with a 90% probability of an upward move. Current price: $56.49. Resistance and support levels: $42.40 and $61.15, respectively. Recent trends show a downtrend during October and the week of 10/23/23 - 10/30/23.

In summary, the biotechnology sector, particularly represented by CLLS, EDIT, and CRSP, has recently demonstrated significant growth. Positive technical indicators, substantial volume increases, and notable price movements contribute to the overall optimism in this sector.

Related Ticker: CLLS, EDIT, CRSP

Momentum Indicator for CLLS turns negative, indicating new downward trend

CLLS saw its Momentum Indicator move below the 0 level on June 12, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In of the 98 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CLLS turned negative on May 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

CLLS moved below its 50-day moving average on June 06, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CLLS crossed bearishly below the 50-day moving average on June 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CLLS entered a downward trend on June 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.148) is normal, around the industry mean (16.950). P/E Ratio (0.000) is within average values for comparable stocks, (59.602). CLLS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (2.726) is also within normal values, averaging (257.570).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.45B. The market cap for tickers in the group ranges from 151 to 355.9B. NONOF holds the highest valuation in this group at 355.9B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 13%, and the average quarterly price growth was 4%. KLTO experienced the highest price growth at 680%, while LYRA experienced the biggest fall at -53%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -37%. For the same stocks of the Industry, the average monthly volume growth was -52% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 59
SMR Rating: 90
Profit Risk Rating: 95
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com
Interact to see
Advertisement
Paper wallets are extremely useful tools – beyond being one of the most popular and secure cold storage methods, they make it simple to transfer coins between owners.You can access the funds on your paper wallet by “sweeping” (or importing) them to either a live wallet (like Trezor or Exodus) or an exchange service (like Coinbase). Most services allow you to import them directly from your wallet’s private key, but there are two key exceptions.
Learn the 27 essential intraday trading rules that every manual trader should master—and discover how Tickeron’s AI platform applies them automatically for consistent, emotion-free execution and smarter, real-time decision-making.
#investment#trading
A $2 trillion sell-off has investors asking: is 2025 the next dot-com crash or a replay of the 2008 recession? This deep dive compares both scenarios, outlines warning signs, and reveals how AI-powered trading strategies can help navigate rising volatility.
#trading#investment
New to trading? Discover 21 powerful lessons every beginner must learn—and see how Tickeron’s AI Double Agent strategies apply them in real time. From mastering risk to managing emotions, this guide helps you trade smarter, safer, and more confidently.
#investment#trading
From the railroads of the 1920s to the AI giants of 2025, market history shows that extreme concentration often precedes massive bubbles and crashes. This article explores five key turning points and how Tickeron’s AI helps traders navigate today’s bubble-prone landscape.
#investment#trading
U.S. tariff tensions rocked markets this week, sending tech stocks into retreat and safe-haven assets like gold and the yen soaring. As investors brace for major earnings and global policy shifts, volatility remains high across equities, currencies, and commodities.
#investment#trading
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
#investment#trading
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
#investment#trading
Tickeron launches its innovative Double Agent Trading Bot, combining long NVDA trades with hedged NVDS positions. Using AI-driven pattern trading and real-time risk management, the bot achieves a 75% success rate, revolutionizing automated trading strategies.
#trading#investment
Tickeron’s AI trading bots are setting new standards in finance, achieving up to 86.6% win rates across leveraged and sector ETFs. Powered by advanced Financial Learning Models (FLMs), Tickeron’s AI delivers precision, adaptability, and real-time trading success.
#trading
Wall Street expects strong profit growth from the Magnificent Seven tech giants in 2025. Discover how to trade Apple, Microsoft, Amazon, Nvidia, Tesla, Meta, and Alphabet using AI-powered Double Agent strategies and smart hedging with inverse ETFs like QID.
On May 2, 2025, a diverse group of companies across energy, financial services, basic materials, consumer discretionary, and healthcare will release their Q1 2025 earnings.
In April 2025, five tech giants—NVIDIA, Tesla, Meta, Palantir, and Amazon—each surged over 40%, driven by AI breakthroughs, strong earnings, and market momentum. Discover what fueled the rally and how Tickeron’s AI trading bots helped investors outperform even these star stocks.
#investment
Markets ended April with mixed signals—gold slid on trade optimism, Big Tech lifted the Nasdaq, and Bitcoin steadied near $94K. With U.S. GDP contracting and job growth beating forecasts, investors brace for more volatility amid tariffs and central bank moves.
In a turbulent market, Tickeron's AI-powered Double Agent Bot is outperforming traditional strategies. Leveraging real-time intraday signals and inverse ETFs, the bot posted a +9.77% quarterly gain while the S&P 500 dropped 9.28%. Here's how AI is reshaping trading.
#trading
As Warren Buffett announces his retirement, investors turn to his trusted Buffett Indicator—a ratio of market cap to GDP—as a key gauge of market valuation.
#investment
Markets move in repeating cycles—Accumulation, Uptrend, Distribution, and Downtrend. Learn how to recognize each phase and deploy Tickeron’s AI-powered Double Agent strategy to adapt, protect capital, and profit in any market condition.
#trading
Discover how confirmation trading techniques—like moving average crossovers and volume-backed breakouts—can improve accuracy and reduce false signals. Learn how Tickeron’s AI automates these strategies for smarter, faster, and more disciplined trading.
#trading
Hedge funds are ramping up bearish bets on small-cap stocks, with Russell 2000 short interest hitting new highs. As macro headwinds mount and technical support teeters, Tickeron’s AI Double Agents step in to navigate the looming sell-off with precision.
#investment#trading#artificial_intelligence
SPY’s Momentum Indicator turned bullish on April 25, 2025, signaling a potential trend shift with a 90% historical success rate. This article explores how economic scarcity, technical signals, and AI-driven tools like Tickeron’s A.I.dvisor shape investor decisions in volatile markets.
#trading